Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients
出版年份 2015 全文链接
标题
Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients
作者
关键词
-
出版物
ACTA PHARMACOLOGICA SINICA
Volume 36, Issue 2, Pages 200-208
出版商
Springer Nature
发表日期
2015-01-26
DOI
10.1038/aps.2014.136
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients
- (2014) Chun-Jun Li et al. Cardiovascular Diabetology
- Glucose-Lowering Effects and Low Risk of Hypoglycemia in Patients With Maturity-Onset Diabetes of the Young When Treated With a GLP-1 Receptor Agonist: A Double-Blind, Randomized, Crossover Trial
- (2014) Signe H. Østoft et al. DIABETES CARE
- Independent glucose and weight-reducing effects of Liraglutide in a real-world population of type 2 diabetic outpatients
- (2013) Gian Paolo Fadini et al. ACTA DIABETOLOGICA
- Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin
- (2013) Mojca Jensterle Sever et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Effects of Liraglutide, a Human Glucagon-like Peptide-1 Analogue, on Body Weight, Body Fat Area and Body Fat-related Markers in Patients with Type 2 Diabetes Mellitus
- (2013) Daisuke Suzuki et al. INTERNAL MEDICINE
- Serum creatinine level, a surrogate of muscle mass, predicts mortality in peritoneal dialysis patients
- (2013) Jongha Park et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Waist Circumference Independently Associates with the Risk of Insulin Resistance and Type 2 Diabetes in Mexican American Families
- (2013) Manju Mamtani et al. PLoS One
- Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity
- (2012) Chun-jun Li et al. Cardiovascular Diabetology
- Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme
- (2012) K. Niswender et al. DIABETES OBESITY & METABOLISM
- Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study
- (2012) M. Nauck et al. DIABETES OBESITY & METABOLISM
- Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes
- (2012) R. E. van Genugten et al. DIABETES OBESITY & METABOLISM
- Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2012) S. E. Inzucchi et al. DIABETOLOGIA
- Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes
- (2010) B. W. Bode et al. DIABETES OBESITY & METABOLISM
- Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, doubl
- (2010) W. Yang et al. DIABETES OBESITY & METABOLISM
- Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
- (2009) B. Zinman et al. DIABETES CARE
- Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue
- (2009) J. Jendle et al. DIABETES OBESITY & METABOLISM
- Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
- (2009) M. Marre et al. DIABETIC MEDICINE
- Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
- (2009) D. Russell-Jones et al. DIABETOLOGIA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now